Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia. (Q38783043)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998623 AND SRC:MED&resulttype=core&format=json

12 March 2020

title

Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998623 AND SRC:MED&resulttype=core&format=json

12 March 2020

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

author

Benito Almirante

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998623 AND SRC:MED&resulttype=core&format=json

12 March 2020

Vicenç Falcó

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998623 AND SRC:MED&resulttype=core&format=json

12 March 2020

Joaquin Burgos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998623 AND SRC:MED&resulttype=core&format=json

12 March 2020

Ricard Ferrer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998623 AND SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Elisabeth Papiol

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998623 AND SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

English

0 references

publication date

1 April 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998623 AND SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998623 AND SRC:MED&resulttype=core&format=json

12 March 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998623 AND SRC:MED&resulttype=core&format=json

12 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998623 AND SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

653-665

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998623 AND SRC:MED&resulttype=core&format=json

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Nosocomial lung infections in adult intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Defining, treating and preventing hospital acquired pneumonia: European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Current guidelines for the treatment of severe pneumonia and sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Review of recent clinical trials of hospital-acquired pneumonia and ventilator-associated pneumonia: a perspective from academia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Global spread of Carbapenemase-producing Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Carbapenemase-producing Enterobacteriaceae: a call for action!

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Metallo-β-lactamases: a last frontier for β-lactams?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Ventilator-associated pneumonia: present understanding and ongoing debates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Update on management options in the treatment of nosocomial and ventilator assisted pneumonia: review of actual guidelines and economic aspects of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Inadequate treatment of ventilator-associated and hospital-acquired pneumonia: risk factors and impact on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Guideline-adherent initial intravenous antibiotic therapy for hospital-acquired/ventilator-associated pneumonia is clinically superior, saves lives and is cheaper than non guideline adherent therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Impact of clinical guidelines in the management of severe hospital-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Carbapenemases: the versatile beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized stud

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Combating evolution with intelligent design: the neoglycoside ACHN-490

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Synthesis and spectrum of the neoglycoside ACHN-490

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

In Vivo Efficacy of the Novel Aminoglycoside ACHN-490 in Murine Infection Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Agromyces marinus sp. nov., a novel actinobacterium isolated from sea sediment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Targeting virulence: a new paradigm for antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Type III secretion systems and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

Secretion of the Toxin ExoU Is a Marker for Highly VirulentPseudomonas aeruginosaIsolates Obtained from Patients with Hospital‐Acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2016.1168803

10.1517/13543784.2016.1168803

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ml2avn3prbd6bda2uje2zsgq5m

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_ml2avn3prbd6bda2uje2zsgq5m

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ml2avn3prbd6bda2uje2zsgq5m

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/ml2avn3prbd6bda2uje2zsgq5m

1 reference